TITLE

BMS, Novartis restructuring

PUB. DATE
February 2008
SOURCE
Pharmaceutical Representative;Feb2008, Vol. 38 Issue 2, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the restructuring of two pharmaceutical company Bristol-Myers Squibb Co. and Novartis AG. Bristol-Myers Squibb Co. announced a strategic initiative that focuses on the company's efforts and cutting $1.5 billion in pre-tax costs by 2010. On the other hand, Novartis AG is planning to reduce its operations, remove organizational layers, eliminate 2,500 full-time positions worldwide that could result in pre-tax savings of $1.6 billion in 2010.
ACCESSION #
28816882

 

Related Articles

  • livinglifebetter.com and healthandage.com case studies.  // Livinglifebetter.com & Healthandage.com Case Studies: Reaching a;Mar2004, p1 

    Presents information about two lifestyle web sites, Bristol-Myers Squibb Co.'s livingbetter.com and Novartis AG's healthandage.com. Advantages gained by pharmaceutical companies by employing a lifestyle web site; Description of the web site livinglifebetter.com; Diseases covered by...

  • World News & Analysis. Gopal, Kevin // Pharmaceutical Executive;Nov2000, Vol. 20 Issue 11, p34 

    Presents updates on the pharmaceutical industry as of November 2000. Plan of Akzo Nobel to spin-off Organon, its pharmaceutical division; Information on the plans of Bristol-Myers Squibb to sell its Clairol beauty care business and its orthopedic unit, Zimmer, to focus more on medicines;...

  • Investors rush to generic stocks in a pivotal year.  // Drug Store News;8/28/2000, Vol. 22 Issue 12, p46 

    Provides information on the leading generic manufacturers in the United States. Novartis; Barr Labs; Bristol-Myers Squibb; Watson; Boehringer Ingelheim.

  • BIG PHARMA'S FRENETIC WEEK.  // njbiz;7/29/2002, Vol. 15 Issue 31, p3 

    Presents updates on the pharmaceutical industry, as of July 29, 2002. Criticism against the hormone replacement franchise of Wyeth; Drug approval for Zelnorm by Novartis AG; Earnings of Bristol-Myers Squibb.

  • CORPORATE.  // MondayMorning;3/10/2014, Vol. 22 Issue 9, p2 

    The article presents news briefs related to pharmaceutical companies. Bristol-Myers Squibb Co.'s experimental HIV drug controlled the virus in a study that suggests the medicine may help difficult-to-treat patients. Thoratec Corp. issued an safety advisory about the use of the pocket controller...

  • Novartis, BMS Withdraw IBS Drug from European Review.  // Chemical Market Reporter;6/11/2001, Vol. 259 Issue 24, p8 

    Reports on the decision of Novartis and Bristol-Myers Squibb Co. to withdraw their marketing application for the drug Zelmac from the European Agency for the Evaluation of Medicinal Products. Reason for the withdrawal; Forecast on the sales of Zelmac by 2005; Agreement between Novartis and...

  • BMS' OTC pain meds are Novartis' gain. Arnold, Matthew // Medical Marketing & Media;Aug2005, Vol. 40 Issue 8, p8 

    Reports on Novartis' acquisition of the U.S. and Canadian over-the-counter (OTC) business of Bristol-Myers Squibb. Total value of the deal; Novartis' entry into the U.S. market for adult table headache remedies; Terms under the acquisition deal.

  • Pharma should help pay for cancer Rx. M. A. // Medical Marketing & Media;Mar2010, Vol. 45 Issue 3, p11 

    The article reports on the move of the government regulators to urge Novartis AG and Bristol-Myers Squibb Co. to help pay for their leukemia drugs in Great Britain.

  • BMS cuts 500 reps in specialty switch.  // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p11 

    This article reports that Bristol-Myers Squibb Co. laid off 500 sales representatives and realigned its reduced primary care field force to focus on its cardiology and diabetes products, part of a move to channel the bulk of its efforts into specialty markets. The move comes amid a series of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics